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renal transplant dysfunction, as manifested by a slow, progres-
sive rise in serum creatinine, developed; the decreasing renal
function was associated with proteinuria (1 to 2 g/24 hr). The
erratic cyclosporine levels and blood pressure readings led to
the suspicion that he remained noncompliant with his medica-
tions.
A renal transplant biopsy one year ago (when his serum
creatinine was 4.0 mg/dl and urinary protein-to-creatinine ratio
was 1.2) showed evidence of chronic allograft nephropathy
(Fig. 1). Specifically, the renal parenchyma was greatly distorted
by widespread sclerosis. Most glomeruli were either globally or
segmentally obsolescent or appeared hypoperfused. Extensive
tubular atrophy was present. The interstitium was expanded
by connective tissue and patchy mononuclear cell infiltrates.
Isolated tubules showed evidence of tubulitis. Arteries revealed
extensive intimal proliferation with near obliteration of theCASE PRESENTATION
lumens. Small arteries and arterioles revealed concentric layersA 42-year-old Hispanic man had a history of end-stage renal
of connective tissue or prominent hyaline deposition in the wall.disease secondary to malignant hypertension. He had been
Several vessels showed signs of active inflammation of theon hemodialysis for two years before receiving a 4-antigen
intima (endotheliitis). Results from the renal biopsy along withmismatched, cadaveric renal allograft four years ago. Positive
the progressive decline in renal function prompted a changefor cytomegalovirus (CMV), he received a CMV-negative kid-
in his medications from azathioprine to mycophenolic mofetilney. His serologic hepatitis profile showed positive hepatitis B
(Cellcept), but renal transplant dysfunction progressed, neces-antibody but negative antigen, and negative hepatitis C anti-
sitating reinstitution of hemodialysis therapy.body. His initial post-transplant course was complicated by
delayed graft function and one episode of presumed acute
rejection in the first two weeks post transplant, which re-
sponded to administration of a steroid pulse.
At discharge after transplantation, his serum creatinine level
was at its nadir value of 1.1 mg/dl. Cyclosporine, azathioprine, DISCUSSION
and steroids were initiated and maintained. He developed post-
Dr. Mohamed H. Sayegh (Research Director, Labora-transplant hypertension, which was managed with an angioten-
sin-converting-enzyme inhibitor. Approximately four months tory of Immunogenetics and Transplantation, Renal Divi-
post transplant, he had another acute rejection episode, which sion, Brigham and Women’s Hospital; and Associate Pro-
was believed to be secondary to noncompliance with his medi- fessor of Medicine, Harvard Medical School, Boston,cations, as reflected by erratic cyclosporine levels during his
Massachusetts, USA): This patient is a typical recipientfollow-up clinic visits. Subsequent to that episode, his renal
of a cadaveric renal transplant who ultimately developedtransplant function had been relatively stable (serum creatinine
in the 2.1 to 2.6 mg/dl range). But two years ago, progressive chronic allograft nephropathy that led to a second epi-
sode of end-stage renal disease. Although chronic allo-
graft nephropathy has been recognized for years, only
Key words: chronic allograft rejection, transplant glomerulopathy,
recently have researchers gone back to the bench to trytransplant nephropathy, acute rejection.
to understand the pathophysiologic mechanisms of this
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nephropathy is clinically characterized by progressiveRoussel, Incorporated; Dialysis Clinic, Incorporated; Amgen, Incorpo-
rated; and R & D Laboratories, Incorporated. organ dysfunction associated with proteinuria, hyperten-
sion, and somewhat typical morphologic changes of graft 1999 by the International Society of Nephrology
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arteriosclerosis, glomerulosclerosis, and variable degrees [11, 12]. Therefore, the use of the terminology alloanti-
gen-dependent versus alloantigen-independent is prefer-of interstitial inflammation, fibrosis, and tubular atrophy
[1]. Not unique to the kidney, chronic allograft failure able. In this Forum, I will be mostly focusing on the
role and mechanisms of indirect allorecognition in graftaffects all solid organ allografts including the heart, lung
and, to a lesser degree, the liver [1]. In fact, in other than rejection, particularly chronic rejection.
liver transplant recipients in whom recurrent disease is
Direct and indirect allorecognitiona major problem, chronic allograft dysfunction is the
major cause of graft loss after the first year post trans- The primary initial event that ultimately leads to graft
rejection is allorecognition (T-cell recognition of alloan-plant. Several studies have established the clinical risk
factors of chronic allograft failure. These factors include tigen), in particular, antigens of the major histocompati-
bility complex (MHC). Several other factors can contrib-delayed graft function, acute rejection, infection (such
as CMV), and “underimmunosuppression” with acute ute to the effector mechanisms of graft dysfunction and
ultimately failure, however. Using gene knockout ani-rejection, particularly recurrent and late episodes (be-
yond three months) [2–4]. mals, Krieger et al showed that CD41 T-cells are essen-
tial for initiating allograft rejection [13]. There are twoChronic allograft dysfunction is mediated by both allo-
antigen-dependent factors (recipient-donor incompati- distinct, yet not mutually exclusive, pathways of allorec-
ognition by CD41 T-cells [14–19]. In the so-called “di-bility, acute rejection, underimmunosuppression) as well
as alloantigen-independent factors (ischemia, hyperten- rect” pathway, T-cells recognize intact allo-MHC mole-
cules on the surface of donor antigen-presenting cellssion, reduced nephron mass, hyperlipidemia, infection,
drug nephrotoxicity) [2, 3, 5, 6]. The mechanisms through (APCs) (Fig. 2). Peptides, derived from endogenous pro-
teins including MHC molecules, bound into the groovewhich alloantigen-independent factors contribute to
graft dysfunction have not yet been defined [6]. But it of the MHC play an important role in this mode of
allorecognition [20]. In the so-called “indirect” pathway,is alloantigen-dependent mechanisms that predominate
in initiating and propagating the injury that leads to T-cells recognize processed alloantigen presented as pep-
tides by self APCs (Fig. 2). The basic premise for indirectchronic allograft loss. Perhaps the best evidence support-
ing a dominant role for alloantigen-dependent factors is allorecognition as a mechanism for initiation and/or am-
plification of allograft rejection is that donor alloantigensthe clinical observation that the half-life (defined as the
time when 50% of grafts have failed after surviving the are shed from the graft, taken up by recipient APCs,
and presented to T-cells. The findings in humans [21, 22]first year) of renal allografts decreases with decreasing
degrees of HLA matching, that is, incompatibility, in and in mice [23] that at least some of the peptides eluted
from cell surface class-II MHC molecules represent MHCliving-related as well as in cadaveric grafts [7]. In addi-
tion, patients who demonstrate donor-specific hyporeac- sequences suggest that processing of MHC molecules is
a physiologic event in vivo.tivity exhibit a very low incidence of chronic rejection [8].
Experimental evidence from re-transplantation studies Although no evidence has indicated that T-cells recog-
nizing alloantigens via the direct versus indirect pathwayin rat models of chronic allograft rejection confirms the
importance of alloantigen-dependent mechanisms, par- are predetermined to be biologically different, from the
standpoint of contribution to mechanisms of allograftticularly in initiating the chronic rejection process [9].
Furthermore, data from several experimental animal rejection, these two pathways of allorecognition are dis-
tinct for the following reasons: first, differences existmodels clearly indicate that induction of donor-specific
tolerance prevents development of chronic rejection [10]. in the microenvironment and locale of “professional”
(bone-marrow-derived) APCs (donor versus self) at dif-Therefore, this discussion will focus on alloantigen-depen-
dent mechanisms of allograft dysfunction, particularly ferent times after transplantation; second, direct re-
sponses can be primary or primed (secondary) T-cellthe role of indirect allorecognition mechanisms. In that
regard it is important to clarify some poorly defined termi- responses, while indirect responses are all primed (sec-
ondary) T-cell responses; third, there can be differentnology that has been used in the literature. “Chronic allo-
graft dysfunction” is a generic term that does not imply effects of immunosuppressive or tolerance regimens on
primary versus primed T-cell responses. Therefore, di-causation. “Chronic rejection,” on the other hand, implies
an alloimmune-mediated process driven by the host reac- rect and indirect allorecognition need not be mutually
exclusive pathways, as each is mediated by different setstion against graft antigens. “Immunologic” versus “non-
immunologic” mechanisms have been used interchange- of T-cell clones, and both can be involved in the rejection
process simultaneously or at different times post trans-ably with “alloantigen-dependent” versus “-independent”
mechanisms, respectively, although this terminology is plantation. Mounting evidence indicates that indirect allo-
recognition, analogous to self-restricted T-cell recognitionnot entirely accurate, as several alloantigen-independent
factors mediate injury through inflammatory mecha- of nominal antigens, occurs during allograft rejection. I
will return to this topic later.nisms that involve immune cells and/or their products
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The question is, what are the role and mechanisms of responses when challenged by the allopeptides, but more
interestingly they also had significant DTH responsesindirect allorecognition in rejection? Early acute allo-
graft rejection might be mediated predominantly by the when challenged by allogeneic WF splenocytes, and not
when challenged by syngeneic LEW or third-party allo-direct pathway, as the graft contains a significant number
of donor-derived passenger APCs (particularly dendritic geneic BN (RT1n) splenocytes. Follow-up studies on the
immunogenicity of these synthetic class-II MHC allopep-cells), which express a high density of MHC molecules
and can provide the necessary co-stimulatory signals for tides confirm the occurrence of self-MHC-restricted
T-cell recognition of processed allo-MHC peptides dur-full T-cell activation [19]. Later, when grafts lack passen-
ger (donor) APCS, T-cells primed by the indirect path- ing vascularized cardiac as well as renal allograft rejec-
tion [32, 33]. Splenic CD41 T-cells, taken from LEWway might play the dominant role in the process of
chronic rejection [24]. Definitive evidence proving this recipients of WF vascularized cardiac or renal allografts,
proliferate to specific class-II MHC peptides presentedhypothesis is lacking, however. Braun et al have demon-
strated that “directly” primed CD41 T-cell lines/clones by responder APCs. Our studies also demonstrate that
not all polymorphic peptides are immunogenic. In fact,could effect early acute rejection but not chronic rejec-
tion of passenger-cell-depleted renal allografts [25]. These in LEW responders, only 2 of the 4 RT.1Bub and 2 of
the 4 RT1.Dub were immunogenic [31, 33], and immuno-studies suggest, but do not prove, an important role for
indirect allorecognition in chronic rejection. Other evi- genicity of the individual peptides varied in different
responder strains. These findings suggested to us thatdence that supports a role for indirect allorecognition in
chronic rejection comes from the clinical observation immunogenicity was determined by the responder MHC
haplotype [33]. Benichou et al, using mouse class-IIthat nominal antigen (for example, viral) recognition,
which is analogous to indirect allorecognition, is usually MHC allopeptides [34, 35]; Fabre and colleagues [36, 37]
and Shirwan et al [38], using rat class-I MHC allopep-intact in transplant recipients undergoing maintenance
immunosuppression, and that in-vitro T-cell responses tides; and Ghobrial et al, using soluble rat class-I MHC
molecules [39], have reported similar results indicatingto nominal antigen may correlate with chronic allograft
rejection [26–28]. I will address this issue in a moment. the occurrence of indirect allorecognition during rejec-
tion of skin and vascularized allografts. More recently,
Occurrence of indirect allorecognition we demonstrated indirect allorecognition in an experi-
mental model of acute rejection due to discontinuationInitial studies in the mouse model showed that adop-
tive transfer of syngeneic plastic adherent splenocytes of immunosuppression [40]; this model mimics events
in noncompliant patients. In summary, ample evidenceprimed by the indirect pathway in vivo could sensitize
a recipient to reject skin allografts in an accelerated indicates that indirect allorecognition occurs during allo-
graft rejection. The question is, what is the role andfashion [29]. In another report, LEW (RT11) rats primed
by immunization with soluble class-I or class-II allo- function of T-cells activated via the indirect pathway in
the process of allograft rejection?MHC molecules derived from allogeneic DA (RT1.Aav1)
rats produced antibodies to the soluble allo-MHC mole-
Role and mechanisms of indirect allorecognitioncules and rejected specific skin allografts in an acceler-
ated fashion [30]. Both those studies suggest that self- Elegant studies by Auchincloss et al, using class-II
MHC-deficient mice as donors in a skin allograft model,restricted T-cell recognition of processed allo-MHC mol-
ecules plays a role in allograft rejection. The availability showed that indirect allorecognition by host CD41
T-cells of donor class-I MHC antigens can initiate rapidof MHC sequences has allowed synthesis of MHC-
derived peptides for studying the role and mechanisms skin allograft rejection [41], and that these cells can help
generate cytotoxic T-lymphocytes against donor class-Iof indirect allorecognition in graft rejection. Our initial
studies focused on studying the immunogenicity of syn- MHC [42]. In a separate study, the same investigators
showed that IgG alloantibody production is dependentthetic class-II MHC allopeptides in vivo [31]. Inbred
LEW (RT1) rats, used as responders, were immunized on CD41 T-cells recognizing peptides of donor antigens
through the indirect pathway [43]. Dalloul et al, alsoin the foot pad with a mixture of eight polymorphic
synthetic (25mer) class-II MHC allopeptides. These se- using MHC knockout animals, showed that CD41
T-cells can reject skin allografts through indirect allorec-quences represent the full length of the hypervariable
domains of RT1.Bu (DQ and I-A like) and RT1.Du (DR ognition [44]. Taken together, these data strongly suggest
that, in the absence of direct allorecognition, CD41and I-E like) b chains of the WF (RT1u) rat. Responder
T-cells harvested from popliteal and inguinal lymph T-cells primed by the indirect pathway can initiate allo-
graft rejection, and that either class-I or class-II donornodes of immunized animals exhibited significant prolif-
eration to the MHC allopeptides in vitro when presented antigens can be recognized by CD41 T-cells after pro-
cessing and presentation by recipient class-II MHC mole-by self APCs. In vivo, peptide-immunized LEW animals
mounted significant delayed-type hypersensitivity (DTH) cules on self APCs.
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Fig. 1. Graft morphology. (A) This photo-
graph illustrates extensive tubular atrophy.
Tubular basement membranes are thickened
and the interstitium is expanded by connective
tissue. (B) Arteries reveal extensive accumu-
lation of connective tissue in the media and
in the expanded intima, resulting in substantial
narrowing of the lumen. (C) Glomeruli also
reveal obsolescence of the capillary that results
in global or segmental glomerulosclerosis. The
collapsed capillaries often entrap hyaline ma-
terial, as depicted in this glomerulus with seg-
mental sclerosis (PAS stain, 3400; courtesy of
Dr. H.G. Rennke, Department of Pathology,
Brigham and Women’s Hospital and Harvard
Medical School, Boston, MA, USA).
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Studies with synthetic class-I MHC peptides derived ingly, in addition to the severe interstitial cellular rejec-
tion, animals primed with the immunogenic class-IIfrom the DA rat strain showed that peptide-immunized
LEW rats were capable of rejecting DA skin allografts MHC peptides had severe vascular rejection compared
with control animals. Specifically, allografts harvestedin an accelerated fashion [45]. Furthermore, peptide-
immunized recipients rejected renal allografts depleted from immunogenic class-II MHC allopeptide-primed re-
cipients showed classic morphologic features of vascularof donor-derived interstitial dendritic cells [46]. These
findings clearly demonstrate that indirect allorecognition rejection with necrotizing arteritis, including fragmenta-
tion of the elastica, fibrinoid necrosis, and a mild peri-contributes to the rejection of vascularized allografts.
Effector mechanisms of transplant rejection involve cell- adventitial mixed cellular infiltrate. Allografts from this
group showed deposition of IgG (predominantly IgG2b),ular, delayed-type hypersensitivity (DTH) responses, cell-
mediated cytotoxicity, and humoral components [19, 47]. C3, and fibrin throughout the vasculature. By contrast,
acute rejection in unprimed rats was cellular in nature,Once fully activated, CD41 T-helper cells produce cyto-
kines that orchestrate various effector arms of the alloim- with normal vessels on histologic examination, and es-
sentially no endothelial deposition of IgG, C3, or fibrin.mune response (Fig. 2). Activated CD41 T-cells provide
help for CD81 T-cells, B-cells, and monocytes by secre- Our morphologic and immunohistologic data suggest an
important role for alloantibodies in the accelerated vas-ting cytokines and by initiating cell-cell contact-depen-
dent mechanisms. Activated monocytes release a variety cular rejection observed in animals primed with immuno-
genic donor class-II MHC allopeptides.of noxious agents that mediate tissue injury. B-cell allo-
antibody production ultimately results in complement and We also examined the T-cell proliferative response to
the peptides in primed and control animals. Interestingly,cell-mediated cytotoxicity. Activated CD81 T-cells kill
graft cells in an antigen-specific manner through direct we observed lymphocyte proliferation against peptides
known to be immunogenic in both the peptide-immu-recognition of class-I MHC molecules on target donor
cells. Therefore, CD41 T-cells activated via the indirect nized animals and in the animals primed in vivo by the
transplanted organ, as previously described [32, 33]. How-pathway may effect allograft rejection by DTH and allo-
antibody-mediated mechanisms independent of direct allo- ever, the degree of proliferation to the peptides was
significantly higher in the peptide-immunized group. Thus,recognition. First, we examined whether priming through
the indirect pathway by immunization with donor-derived peptide immunization markedly increased the precursor
frequency of allopeptide-reactive T-cells compared withMHC allopeptides could accelerate acute rejection in an
experimental vascularized cardiac allograft model in the that seen in in-vivo priming as a result of rejecting a
graft [48]. This increased precursor frequency might playrat [48]. We immunized LEW recipients of WF hetero-
topic cardiac allografts with a mixture of the immuno- an essential role in initiating the effector mechanisms
that accelerate the rejection process (Fig. 3).genic (25mer) WF MHC class-II peptides (RT.1Dub1-25,
RT1.Dub20-44, RT1.Bub1-25, and RT1.Bub20-44) in com- To study DTH mechanisms, we generated alloreactive
T-cell clones by in-vivo priming via the indirect pathwayplete Freund’s adjuvant seven days before transplanta-
tion. The control group was immunized with adjuvant and [49]. Inbred LEW rats were primed in vivo by immuniza-
tion in the foot pad with the immunogenic synthetic class-IIsaline or with a mixture of the nonimmunogenic peptides
in adjuvant. The animals received cyclosporine, 5 mg daily MHC allopeptide (RT1.Dub, residues 20-44). This is the
same peptide that alone is effective in priming animalsfor seven days; immunosuppression was discontinued
thereafter. Animals immunized with the immunogenic to accelerate allograft rejection [48]. One week later, we
harvested the primed lymphocytes from the drainingpeptides rejected their allografts in an accelerated fash-
ion; animals immunized with the nonimmunogenic pep- lymph nodes, and established an RT1.Dub20-44 T-cell
line by repeated stimulation with RT1.Dub20-44 peptidetides or adjuvant did not develop accelerated allograft
rejection. No difference existed in the time course of the presented by responder APCs. The T-cell line prolifer-
ated significantly to the RT1.Dub20-44 peptide but notrejection process when recipients were challenged with
third-party BN cardiac allografts, so we deduced that the to a specificity control peptide derived from the RT1.B
locus (RT1.Bub20-44) when presented by self APCs.effect observed was a specific response to donor class-II
MHC peptide priming. Additional studies showed that In addition, the T-cell line produced significant amounts
of IFN-g but not IL-4 upon restimulation with thepriming with the immunogenic RT1.Dub (HLA-DR-like)
peptides, and specifically with the most immunogenic RT1.Dub20-44 peptide. By limiting dilution, we then gen-
erated T-cell clones from this Th1 line. Flow cytometricsingle peptide (RT1.Dub, residues 20-44), was responsible
for the observed acceleration of the rejection process [48]. analysis with specific monoclonal antibodies showed that
all RT1.Dub20-44-specific T-cell clones were CD41. SixMorphologic evaluation of cardiac allografts harvested
from animals at the time of rejection revealed interstitial clones proliferated specifically to the RT1.Dub20-44 pep-
tide and produced IFN-g but not IL-4 when restimulatedcellular rejection of significantly greater intensity in the
accelerated compared with the control groups. Interest- with RT1.Dub20-44 peptide in vitro (that is, Th1 clones).
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Fig. 3. Contribution of indirect allorecogni-
tion to graft rejection: A working hypothesis.
(Adapted from [48] with permission.)
Using RT-PCR transcript analysis with specific rat TCR repertoire: Vb 4, 8.2, or 9. In comparison, the clones
generated from T-cell lines of RT1.Dub20-44-immunizedVb primers, we showed that all these clones expressed
Vb 9 TCR transcripts. These clones are self-restricted LEW rats all expressed TCR Vb 9 only. Adoptive transfer
of T-cell clones expressing TCR Vb 9 or Vb 8.2 to naı¨veand do not proliferate to intact donor (WF) cells in
vitro; thus, they recognize RT1u alloantigens through LEW animals elicited significant DTH responses after
challenge with the RT1.Dub20-44 peptide or allogeneicthe indirect pathway only. We then injected naı¨ve LEW
animals with 25 to 30 3 106 cells intraperitoneally of one WF (RT1u) splenocytes. By contrast, TCR Vb 4-express-
ing clones elicited no DTH response. These data indicateof the RT1.Dub20-44-specific T-cell clones (clone 2F4).
Five days later, the animals were challenged with that not all Th1 clones are pathogenetic; some clones
transfer DTH responses while others do not. This impor-RT1.Dub20-44 in the ear to check for DTH responses.
These animals mounted significant DTH responses to tant observation might explain why priming animals with
the RT1.B peptides, although immunogenic, did not ac-the allopeptide, but not to control antigen. More interest-
ingly, LEW animals injected with the 2F4 clone had celerate allograft rejection [48]. The exact reasons why
a clone is not pathogenetic are unknown, but preliminarysignificant DTH response to re-challenge with irradiated
allogeneic WF spleen cells, but not to syngeneic LEW studies suggest that pathogenicity is related to affinity
of the particular TCR binding to the peptide1MHCor third-party BN splenocytes. This was the first demon-
stration that MHC allopeptide-specific Th1 cell clones complex on APCs [50].
In summary, CD41 T-cells primed by donor peptidestransfer a DTH response. The specific response to WF
cells indicates processing and presentation of allo-MHC via the indirect pathway help monocytes and B-cells to
effect DTH responses and produce donor-specific allo-by self APCs in vivo.
We recently focused our studies on generating T-cell antibodies, respectively. These cellular and humoral
mechanisms contribute to graft rejection. It is also possi-clones from animals primed in vivo by rejection of vascu-
larized allografts, because this is the physiologic pathway ble that such CD41 T-cells help activate CD81 cytotoxic
T-cells which, through direct allorecognition of class-Iof priming to donor-derived peptides [50]. We generated
self-restricted class-II MHC allopeptide-specific T-cell MHC-bearing donor cells, contribute to allograft de-
struction by cytotoxicity [40].clones (to the same peptide, RT1.Dub20-44) from the
spleen and kidney of LEW (RT11) rats undergoing acute
Human studiesrejection of MHC-incompatible WF (RT1u) renal allo-
grafts. All the clones that specifically proliferated to the The first report of self-restricted T-cell recognition of
processed allo-MHC in humans was published by depeptide (RT1.Dub20-44) were CD41 and produced
IFN-g but not IL-4 upon restimulation with the peptide Koster et al, who produced T-cell clones primed by a
synthetic peptide derived from the hypervariable domainin vitro. The Th1 clones from splenic and renal T-cell
lines of rejecting animals expressed a restricted TCR Vb of the b chain of HLA-DR3 (residues 67–85) [51]. These
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Table 1. Indirect alloreactivity to donor HLA-DR peptides in renalclones were capable of proliferating to the allo-MHC
transplant recipients with chronic allograft dysfunctiona
peptide presented by self HLA-DP class-II molecules.
Positive reactivityLiu et al used synthetic MHC peptides (20-25mer) de- HLA-DR Serum
Group No. mismatch creatinine No. Percentagerived from the hypervariable domain of DRb1*0101 to
establish in vitro a T-cell line from an HLA-DR11/DR12 1 11 1 3.0260.61 9 82b
2 10 1 1.7960.15 0 0responder that recognized a specific MHC allopeptide
3 5 2 2.8860.53 0 0(residues 21–42) in the context of self class-II MHC [52].
4 18 2 1.4860.11 2 11
This line also was capable of recognizing cells expressing
a Adapted from Ref. 48
DRb1*0101, from which the peptide sequences were de- b P , 0.0001
rived in the presence of autologous APCs, or in the ab-
sence of autologous APCs only when expressed together
with DR11. These data thus suggest the self-restricted
demonstrated epitope spreading, results comparable torecognition of processed allo-MHC. Responder cells
the observations of Liu et al in patients with acute cardiacwere shown to be CD41 and were inhibited by specific
allograft rejection [54]. More recent work from the sameanti-DR11 monoclonal antibody. Restricted TCR Vb
group examined the relationship among allopeptide re-usage by the responding cell line also was noted [53].
activity, epitope spreading, and chronic rejection in hu-Lessons learned from these in-vitro studies and in-vivo
man cardiac allograft recipients. Utilizing synthetic pep-animal studies utilizing synthetic MHC peptides have
tides corresponding to the hypervariable region of 32been extended into the human transplant arena. Liu and
HLA-DR alleles, they followed donor-specific MHC al-colleagues have demonstrated donor-specific MHC allo-
lopeptide lymphocyte responses in a population of 34peptide T-cell reactivity in humans with recurring epi-
heart allograft recipients. T-cells from sequential sam-sodes of acute cardiac allograft rejection [54]. More inter-
esting was the demonstration of shifting T-cell responses ples of blood collected from the patients as long as 36
to different allopeptides with time. Such a change in the months after transplantation were studied in limiting
pattern of T-cell responses has been termed epitope switch- dilution analysis for allopeptide reactivity. The incidence
ing or spreading and can occur to peptides representing of coronary artery vasculopathy was significantly higher
alternative regions within a given MHC b chain hyperva- in patients who displayed persistent alloreactivity late
riable region (intramolecular spreading) or alternatively, after transplantation (after six months) than in patients
to peptides representing different MHC chains (intermo- who showed no alloreactivity after the first six months
lecular spreading) [54]. An important observation in after transplantation. Epitope spreading was observed
these human studies is that indirectly primed T-cells are with an increased frequency in patients developing vas-
present at a much lower precursor frequency than are culopathy in less than two years, compared with patients
directly primed T-cells. In fact, Liu et al calculated that without vasculopathy [56]. These studies and our own
such allopeptide-specific T-cells are present at 100 to observations in renal transplant recipients [55] indicate
1000 times lower frequency than that of cells recognizing that indirect allorecognition correlates with, and might
intact (direct allorecognition) allo-MHC [24]. This find- play a key role in, chronic rejection.
ing is consistent with the hypothesis that small numbers
of peptide-primed T-cells are mediating an indolent im-
SUMMARYmune response that reflects the natural history of chronic
Taken together, these experimental observations inrejection, a phenomenon characterized by slowly pro-
animals as well as humans have led to the formulationgressive organ dysfunction.
of a hypothesis linking MHC-allopeptide-primed T-cellsWe then studied indirect allorecognition in human
and chronic rejection (Fig. 4). Small numbers of indi-renal allograft recipients with chronic rejection [55]. We
rectly primed T-cells are present and targeted against afound that peripheral blood lymphocytes from 82% of
restricted repertoire of immunodominant peptides in thepatients who were mismatched for at least one of 3 DR
immediate post-transplant period. Concomitant with themolecules and who had chronic allograft dysfunction
possible decline in the importance of directly primedspecifically proliferated to the mismatched allopeptides
T-cells with time post engraftment [40, 57], the precursor(N 5 9/11). Proliferation was seen in only 6% of control
frequency of indirectly primed T-cells continues to besubjects (2/33, P , 0.0001) (Table 1). The precursor
low grade. In addition, naı¨ve CD41 T-cells recognizefrequency of peptide-specific T-cells was more than ten-
new epitopes, by a yet unclear mechanisms, and are con-fold higher in patients with chronic rejection as com-
tinuously becoming activated while immunosuppressionpared with controls. These data demonstrated for the
is being reduced. Activated CD41 T-cells provide helpfirst time that T-cells of patients with chronic graft dys-
and in turn activate the effector mechanism of allograftfunction are primed to recognize and respond to specific
donor-derived MHC allopeptides [55]. Our study also destruction, namely, monocytes/macrophages (DTH),
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Fig. 2. Mechanisms of allorecognition and
graft rejection. (Adapted from [19] with per-
mission.)
Fig. 4. Role of indirect allorecognition in
chronic allograft rejection: A working hypoth-
esis. (Adapted from [67] with permission.)
B-cells (alloantibodies), and endothelial and smooth mus- We can draw several implications from this working
hypothesis. First, to prevent chronic allograft rejection,cle cells. Through complex cellular and molecular mecha-
nisms [58], which include tissue injury, healing, and repair, we need to specifically target the indirect pathway. In
addition, it is likely that such interventions will have tothe grafts develop morphologic changes of chronic rejec-
tion that lead to clinical organ dysfunction and failure. be introduced at a relatively early stage prior to epitope
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shifting. Several strategies hold promise in that regard. mune response for therapeutic purposes, it may have
significant clinical relevance to several immune-medi-In particular, strategies targeted at blocking CD28-B7
and/or CD40L-CD40 T-cell co-stimulatory activation ated diseases.
Dr. Madias: Since CTLA4 provides an inhibitory sig-have been shown to prevent development [59–64] and
even interrupt progression [65] of chronic rejection in nal to activated T-cells, what about a strategy of blocking
the B7-CD28 pathway but allowing the engagement ofexperimental animals. Interestingly, targeting T-cell co-
stimulatory activation also might be effective in amelio- B7-CTLA4 or even enhancing the expression of CTLA4
inhibitory receptor on activated T-cells?rating injury mediated by alloantigen-independent mecha-
nisms of graft dysfunction, such as ischemia/reperfusion Dr. Sayegh: This is a very important issue as well.
If you target B7, then you are actually inhibiting bothinjury [11, 12]. Obviously, the applicability of these ro-
dent studies needs to be confirmed in large animals [66] pathways, CD28 and CTLA4. In certain circumstances,
delaying the administration of CTLA4Ig is more effec-before clinical trials in humans are begun.
tive than giving it early on. Our hypothesis is that this
delay allows CTLA4 to be expressed on T-cells. We have
QUESTIONS AND ANSWERS
recent data showing that if we block CTLA4, we can
Dr. Nicolaos E. Madias (Chief, Division of Nephrol- abrogate the beneficial effects of CTLA4Ig [68]. It is
ogy, New England Medical Center, Boston, Massachu- possible that the timing of expression of CTLA4 vis-a-
setts): Thank you for this wonderful presentation. Can vis B7 blockade is a critical issue.
you expand on the determinants of the immunogenicity Dr. Andrew S. Levey (Division of Nephrology, New
of processed allo-MHC antigens? What might be the England Medical Center): It seems to me that you have
mechanism of the epitope spreading you described as a shown very nicely the indirect pathway of allorecognition
function of time? in various models. However, I’m not sure that you clearly
Dr. Sayegh: I could hypothesize on potential mecha- differentiated its relative importance in acute versus
nisms. One possibility, for example, is that acute rejec- chronic rejection, although your presentation suggests
tion, infections (such as CMV), or potentially ischemic that you favor the hypothesis that it might be a dominant
injury to the graft can upregulate MHC expression. This and unsuppressed mechanism in chronic rejection. Would
upregulation can lead to increased shedding of MHC you agree that the clinical data that you presented prove
molecules, which in turn can result in a different type that the indirect mechanism of allorecognition occurs
pattern of peptide reactivity because hidden epitopes are but doesn’t discriminate whether this is important in
now exposed. In addition, changes in immunosuppression acute versus chronic rejection?
or other factors with time can affect T-cell recognition On a broader scope, it seems to me that acute and
of different epitopes. The bottom line is that the precise chronic rejection clearly differ with regard to pathologic
mechanisms of epitope spreading remain unknown. patterns and the immune effector pathways, but is there
Dr. Madias: It would appear that both the distribution any evidence that the initiation of the injury differs? Is
and the timing of expression of the various costimulatory it possible that both direct and indirect allorecognition
signals are of importance. What do we know about the occur in all phases of rejection? Does the separation of
mechanism of expression of B7 molecules on activated acute and chronic rejection as clinical entities make any
APCs and endothelium and of CTLA4 inhibitory recep- difference?
tors on activated T-cells? Dr. Sayegh: Yes, I do believe there is a difference.
Dr. Sayegh: We know, for example, that cytokines There’s a fundamental pathophysiologic difference that
are important in controlling the upregulation of costimu- we don’t understand very well and that is at least mani-
latory molecules. We recently published two studies in fested by the different morphology and pathology that
which we looked at ischemic injury and its effect on B7 we see. Let me go back to the issue of the relative contri-
expression [11, 12]. Both studies were in a setting in bution of each pathway. I do believe that both pathways
which there was no alloimmune response. We found are operative in the acute setting. In fact, as I said before,
that renal ischemic injury not only upregulates MHC available data support strongly the contribution of the
expression but also upregulates B7 expression. When indirect pathway to acute rejection. But I favor the hy-
we gave animals with ischemic injury to their kidneys pothesis that in the acute setting, because of the high
systemic CTLA4Ig, we ameliorated the ischemic reper- number of antigen-presenting cells in donor organs like
fusion injury in the absence of an alloimmune response. dendritic cells, which express high-density MHC and co-
We think this decrease in reperfusion injury is because stimulatory molecules, the direct pathway is dominant.
of inhibition of the cytokine/chemokine surge. Not a lot We know at the precursor frequency levels that T-cells
is known about what regulates CTLA4 upregulation. responding via the direct allorecognition pathway are
This is a very important area because if we can figure a much higher in number than those responding via the
indirect pathway. In the chronic phase, the importanceway to use a physiologic pathway to terminate the im-
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of the direct pathway is reduced. For example, we know (IL-4, IL-10). We are trying to simplify this method and
generate what we call “mini” T-cell lines to develop newthat the graft lacks donor APCs several weeks after
transplantation. The endothelial cell can function as a immuno-surveillance assays of transplant patients. The
answer to your second question is yes, there are waysdirect APC, but some data from heart transplant patients
showed that many patients with chronic rejection are to serially measure the degree of inhibition of the indirect
pathway, but they are not very well developed.“tolerant” to the direct response, as suggested by the
precursor frequency analysis against donor cells [57]. Dr. Andrew J. King (Division of Nephrology, New
England Medical Center): One strategy that has beenBecause these patients cannot mount a direct response,
the chronic rejection that occurs must be driven by indi- employed over the years, and especially prior to the
introduction of cyclosporine, was pre-transplant donorrect allorecognition.
At this moment, we cannot definitively answer the blood transfusion. There is evidence of a beneficial effect
of this approach in preventing solid organ rejection, par-question of what is the relative contribution of direct
versus indirect alloresponses to acute versus chronic re- ticularly with one-haplotype-matched transfusion heart
transplant recipients. Could you speculate on how thisjection. My fundamental point is that a pathway exists
that has been forgotten for years—indirect allorecogni- might work in relation to your model? Could this practice
in some way inhibit epitope shifting?tion—and that it probably plays a major role in chronic
rejection. To exaggerate a bit for effect, I don’t think Dr. Sayegh: It has been known for years that if you
give donor antigen in the form of bone marrow or bloodanybody cares substantially anymore about acute rejec-
tion; the major problem now is chronic rejection. transfusion, you can induce tolerance in the recipient
animal. The limited data in humans have not been repro-Dr. Madias: Is there cross-talk between the two path-
ways of allorecognition? Is it possible for recipient APCs ducible. The implication of our studies is that if one does
not induce tolerance to the indirect response, prolongedto provide costimulation of T-cells that have been primed
by the direct allorecognition pathway? survival is likely, but the patient will probably end up
developing chronic rejection. This also means that anyDr. Sayegh: Yes, this is called trans-costimulation. If
the T-cell gets a costimulatory signal from the same APC, tolerance strategy that succeeds in preventing acute and
chronic rejection has to induce tolerance to both directit’s called “costimulation in cis.” The two pathways do
talk to each other. The best demonstration of this is at and indirect responses. In recent studies, we showed that
administration of donor antigen was necessary to inducethe endothelial cell level. The endothelial cell is of donor
origin, while the monocytes and T-cells are of recipient tolerance and prevent chronic rejection [70].
Dr. King: In your review of chronic rejection, youorigin; they go through the endothelium to reach the
graft. Indeed, recent data in collaboration with the labo- referred to the characteristic vascular lesion with intimal
proliferation and an inflammatory response. What is theratory of Dr. Briscoe at Children’s Hospital in Boston
show that endothelial cells can promote indirect allorec- nature of the cells in that lesion? Are these T-cells with
CD41 markers? Are there CD81 cells there?ognition [69].
Dr. John T. Harrington (Dean, Tufts University Also, you implied that antibody production and B-cells
play a role in this chronic rejection process. Is there anySchool of Medicine, Boston, Massachusetts): I have two
questions. Could you give me your best estimate of the evidence that antibody-mediated responses are oc-
curring within the histologic lesion itself?quantitative degree of importance of the indirect allorec-
ognition pathway in chronic rejection? Is it 50/50, 90% Dr. Sayegh: The intimal lesions themselves reflect
predominantly smooth muscle cell proliferation. Thedirect, 90% indirect, or is there no way of knowing?
Second, are there clinical methods that would allow us smooth muscle cells around the intima proliferate and
expand and they push the intima inside. Immunohisto-to serially measure the degree of inhibition of the indirect
allorecognition pathway? logic staining reveals the presence of CD41 T-cells and
monocytes/macrophages but not a lot of CD81 cells.Dr. Sayegh: To answer your first question, these stud-
ies have not been done. However, we hypothesize that Dr. David Adams and Dr. Mary Russell have looked at
the transition in cell expression in the lesion. Early on,indirect allorecognition is the predominant pathway in
chronic rejection. Whether the direct response also con- you find mostly CD41 T-cells, some monocytes, no or
very few CD81 T-cells; with progression of the lesion,tributes remains unknown.
We have more data now that have not been published there are usually more monocytes/macrophages, and
fewer CD41 T-cells. The IgG antibodies play a veryyet. In work similar to our rat studies, we generated
T-cell lines and clones from patients. We took these important role; in fact, studies using the more refined
ELISA assay show that you can correlate anti-donorcell lines from stable patients and those with chronic
rejection. We found that in patients with chronic rejec- IgG responses with the appearance of chronic rejection
[71]. We think that this antibody response is a surrogatetion, the T-cell lines secrete TH1 cytokines (IL-2, IFN-g).
The stable patients, however, secrete TH2 cytokines for CD41 indirect alloresponses, as previously shown [43].
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Dr. Annamaria Kausz (Division of Nephrology, New Dr. Sayegh: It binds to B7 molecules and causes T-cell
anergy in vitro. There are no data regarding a directEngland Medical Center): Evidently, some data suggest
that the half-life of HLA-identical kidney transplants effect on B-cells.
Dr. Harrington: When you were talking about thewas better in 1974 than in 1996. Could this be due to
the effect of cyclosporine nephrotoxicity? immunogenicity of some of the peptides, you mentioned
that a difference in only two amino acids led to a differentDr. Sayegh: The number of these patients was very
small, and thus a firm conclusion cannot be drawn. degree of immunogenicity. Do we know anything about
the structure of those particular proteins and how thatDr. Kausz: You mentioned brain death as a possible
cause of antigen-independent allograft dysfunction. Is minimal quantitative amino acid difference leads to such
a powerful functional difference?there an immunologic mechanism behind that?
Dr. Sayegh: We recently published a paper on this Dr. Sayegh: We have gone beyond that and split the
peptides into two peptides. Each one has only one aminoissue [72]. We used a rat model of so-called “explosive”
brain death. These animals developed shock and hypo- acid difference, and you get the same immune response
with one amino acid difference between donor and recip-tension, hypoperfusion of the organs, and severe ische-
mic injury. The organs of these animals showed upregula- ient [50]. That’s not unusual because these are probably
linear structures that are being recognized and bound totion of inflammatory cytokines and chemokines within
hours after the injury. HLA molecules of the recipient APCs. What is being
recognized as foreign is the substituted amino acid. TheDr. Bertrand L. Jaber (Division of Nephrology, New
England Medical Center): If one assumes that alloantigen T-cell receptor thus needs only to encounter one poly-
morphic amino acid to mount an immune response. Thiscell-surface shedding is a prerequisite for indirect allo-
recognition, what are the factors that determine cell- phenomenon has been shown in mutation studies. You
can substitute only one amino acid in a molecule andsurface shedding besides acute rejection?
Dr. Sayegh: This has not been studied. yet induce a vigorous immune response. This is not in-
consistent at all.Dr. Jaber: It has been shown that many of the mem-
brane-bound cytokine receptors are cleaved off the cell Dr. Madias: Could you please comment on the most
promising strategies for induction and maintenance ofsurface to become soluble following activation of metallo-
proteinases. It would be interesting to examine whether tolerance and the potential mechanisms involved?
Dr. Sayegh: There are several strategies to try to in-cell-surface shedding of alloantigens is indeed regulated
by putative metalloproteinases. The possible modulation duce tolerance, but some of the clinically promising ones
include blocking T-cell costimulation, donor bone mar-of this phenomenon by metalloproteinase inhibitors
could lead to the development of new therapeutic strate- row chimerism, donor-specific transfusions coupled with
immunomodulatory strategies, and some humanizedgies that limit indirect allorecognition.
Dr. Sayegh: Yes. In support of that hypothesis, we monoclonal antibodies [73]. The translation of these
strategies from small animals in the laboratory to pri-know through association studies that levels of soluble
donor MHC molecules correlate with chronic rejection. mates and humans remains an elusive goal.
Dr. King: One strategy employed in patients who have
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